NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

TerminatedN/A

Sponsor: Pfizer

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Sunitinib

Countries: Algeria, Egypt, Kuwait, Morocco

OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related QoL in the real life setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

* Inclusion Criteria:

  1. Patients being treated with SU as 1st line treatment according to the approved therapeutic indication.
  2. Histologically confirmed diagnosis of mRCC (clear cell RCC as well as nonclear cell RCC) with measurable disease according to RECIST 1.1
  3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

     Exclusion Criteria:

  <!-- -->

  1. Patients being treated with cytokines or any other treatment other than SU in 1st line setting
  2. Patients presenting with a known hypersensitivity to SU or its metabolites will not be included in the study per the label.

Locations (8)

Algers, Algeria
Annaba, Algeria
Annaba, Algeria
Cairo, Egypt
Cairo, Egypt
Cairo, Egypt
Kuwait City, Kuwait
Rabat, Morocco